An observational study in Mental Disorder, sponsored by Nadav Goldental. Status unknown. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Nadav Goldental · Observational
The use of blood tests to measure drug concentrations in psychiatric patients is often a crucial part of monitoring and evaluating the course of treatment. Such tests are commonly conducted as part of official protocols, and patients are often tested on a weekly basis.
The current study aims to examine the possibility of using a novel, non-invasive device to measure drug concentrations in exhaled breath as an alternative to blood tests. The device, SniffPhone, uses sensors to detect and measure volatile organic compounds (VOCs) in exhaled breath, and features a small and portable design. Sniff Phone has been previously approved for use in clinical trials and has been used successfully to screen for particular types of cancer and other diseases.
2,148 studies on the registry are indexed under Mental Disorders; 425 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 488 observational studies indexed under Mental Disorders.
Browse Mental Disorders studies →Nadav Goldental is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Psychiatric patients with traetment plans that require theraputic drug monitoring
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Detection of drug type and concentration in volatile organic compounds (VOCs) profile
Detection of drug type and concentration in VOCs profile (measured using Sniff Phone)
Time frame: Up to 6 months
Correlation between drug concentration and volatile organic compounds VOC concentrations
Correlation between drug concentration (as measured in blood test) and VOCs (hexanone acetic acid, heptane, hexanal, 3-heptanone, hexanoic acid, heptanal and nonanal) measured using Sniff Phone.
Time frame: Up to 6 months
No study locations are listed for this record.
Start is estimated for Sep 2019; primary completion for Apr 2020, 7 months later.
Of 188 non-industry observational studies under Mental Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 72. This study's planned 7 months is below that.
Counting every sponsor, half of 193 studies reached it within 42 months; a quarter within 17 and three quarters within 94.
Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nadav Goldental